Company Profile for Aeterna Zentaris Inc.
February 26 2016 - 10:40AM
Business Wire
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We are now conducting Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition of or licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
territories where such out-licensing would enable us to ensure
development, registration and launch of our product candidates. Our
goal is to become a growth-oriented specialty biopharmaceutical
company by pursuing successful development and commercialization of
our product portfolio, achieving successful commercial presence and
growth, while consistently delivering value to our shareholders,
employees and the medical providers and patients who will benefit
from our products. For more information, visit www.aezsinc.com.
Company:
Aeterna Zentaris Inc.
Headquarters Address:
315 Sigma Drive Suite 302D Charleston, SC 29483
Main Telephone:
843-900-3223
Website:
www.aezsinc.com
Ticker:
AEZS(NASDAQ) AEZ(TSX)
Type of Organization:
Public
Industry:
Biotechnology
Key Executives:
Chairman, President & CEO:
David Dodd
SVP, Chief Administrative Officer &
General Counsel: Philip Theodore
SVP & Chief Commercial Officer:
Jude Dinges
Investor Relations
Contact:
Investor Relations
Email:
ir@aezsinc.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160226005007/en/
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2023 to Aug 2024